IgH translocations in multiple myeloma

Peter Leif Bergsagel, Marta Chesi, E. Nardinp, R. S. Lim, O. Shonukan, W. M. Kuehl

Research output: Contribution to journalArticle

Abstract

Based on our summary presentation of the information described above, we propose a working multistep model of the molecular pathogenesis of myeloma (Figure 2). The cell which gives rise to myeloma appears to have passed through the pathway that generates the long-lived plasma cell that has a phenotype similar to myeloma cells. Thus the oncogenic events in myeloma either occur after or do not interfere with the normal maturation process that generates lone-lived plasma cell. Like a long-lived plasma cell, a myeloma cell has undergone three developmentally regulated changes in the DNA structure of the IgH and IgL loci, including productive V(D)J recombination of its IgH and IgL genes, somatic hypermutation of the IgH and IgL V regions, and productive IgH switch recombination to another IgH isotype. It is attractive to speculate that errors in one or more of these processes have caused genetic changes that contribute to the malignant process. A chromosome translocation to the IgH locus, most frequently into a switch region, is a nearly universal event in myeloma cell lines, and it appears to be equally frequent in primary tumor samples. We postulate that these translocations occur at the time of isotype switch recombination, on the non-productive allele. Since MGUS and myeloma share the same legitimate switch recombination on the productive allele, they may also share the same illegitimate switch recombination on the non-productive allele. The result of these translocations is to dysregulate the expression of an oncogene by juxtaposing it to the strong regulatory sequences of the IgH locus, resulting in immortalization of the malignant clone. The presence of intraclonal heterogeneity in the Ig hypervariable regions in MGUS indicates that these cells are still subject to somatic hypermutation. Perhaps spillover of this process onto ras or a tumor suppressor gene on chromosome 13 results in the selection of a single clone for malignant expansion. Following immortalization, the malignant cell establishes a supportive environment in the bone marrow with a network of cytokines, adhesion molecules and other co-stimulatory interactions with the stromal cells. Further mutations lead to stromal cell independent growth, and escape from the bone marrow microenvironment.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalCancer Research Therapy and Control
Volume6
Issue number1-4
StatePublished - 1998
Externally publishedYes

Fingerprint

Multiple Myeloma
Genetic Recombination
Alleles
Stromal Cells
Plasma Cells
Clone Cells
Bone Marrow
V(D)J Recombination
Chromosomes, Human, Pair 13
Molecular Models
Tumor Suppressor Genes
Oncogenes
Chromosomes
Cytokines
Phenotype
Cell Line
Mutation
DNA
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bergsagel, P. L., Chesi, M., Nardinp, E., Lim, R. S., Shonukan, O., & Kuehl, W. M. (1998). IgH translocations in multiple myeloma. Cancer Research Therapy and Control, 6(1-4), 47-52.

IgH translocations in multiple myeloma. / Bergsagel, Peter Leif; Chesi, Marta; Nardinp, E.; Lim, R. S.; Shonukan, O.; Kuehl, W. M.

In: Cancer Research Therapy and Control, Vol. 6, No. 1-4, 1998, p. 47-52.

Research output: Contribution to journalArticle

Bergsagel, PL, Chesi, M, Nardinp, E, Lim, RS, Shonukan, O & Kuehl, WM 1998, 'IgH translocations in multiple myeloma', Cancer Research Therapy and Control, vol. 6, no. 1-4, pp. 47-52.
Bergsagel PL, Chesi M, Nardinp E, Lim RS, Shonukan O, Kuehl WM. IgH translocations in multiple myeloma. Cancer Research Therapy and Control. 1998;6(1-4):47-52.
Bergsagel, Peter Leif ; Chesi, Marta ; Nardinp, E. ; Lim, R. S. ; Shonukan, O. ; Kuehl, W. M. / IgH translocations in multiple myeloma. In: Cancer Research Therapy and Control. 1998 ; Vol. 6, No. 1-4. pp. 47-52.
@article{0325dbc62e764c70a7ab255ed8f0db74,
title = "IgH translocations in multiple myeloma",
abstract = "Based on our summary presentation of the information described above, we propose a working multistep model of the molecular pathogenesis of myeloma (Figure 2). The cell which gives rise to myeloma appears to have passed through the pathway that generates the long-lived plasma cell that has a phenotype similar to myeloma cells. Thus the oncogenic events in myeloma either occur after or do not interfere with the normal maturation process that generates lone-lived plasma cell. Like a long-lived plasma cell, a myeloma cell has undergone three developmentally regulated changes in the DNA structure of the IgH and IgL loci, including productive V(D)J recombination of its IgH and IgL genes, somatic hypermutation of the IgH and IgL V regions, and productive IgH switch recombination to another IgH isotype. It is attractive to speculate that errors in one or more of these processes have caused genetic changes that contribute to the malignant process. A chromosome translocation to the IgH locus, most frequently into a switch region, is a nearly universal event in myeloma cell lines, and it appears to be equally frequent in primary tumor samples. We postulate that these translocations occur at the time of isotype switch recombination, on the non-productive allele. Since MGUS and myeloma share the same legitimate switch recombination on the productive allele, they may also share the same illegitimate switch recombination on the non-productive allele. The result of these translocations is to dysregulate the expression of an oncogene by juxtaposing it to the strong regulatory sequences of the IgH locus, resulting in immortalization of the malignant clone. The presence of intraclonal heterogeneity in the Ig hypervariable regions in MGUS indicates that these cells are still subject to somatic hypermutation. Perhaps spillover of this process onto ras or a tumor suppressor gene on chromosome 13 results in the selection of a single clone for malignant expansion. Following immortalization, the malignant cell establishes a supportive environment in the bone marrow with a network of cytokines, adhesion molecules and other co-stimulatory interactions with the stromal cells. Further mutations lead to stromal cell independent growth, and escape from the bone marrow microenvironment.",
author = "Bergsagel, {Peter Leif} and Marta Chesi and E. Nardinp and Lim, {R. S.} and O. Shonukan and Kuehl, {W. M.}",
year = "1998",
language = "English (US)",
volume = "6",
pages = "47--52",
journal = "Cancer Research, Therapy and Control",
issn = "1064-0525",
publisher = "Harwood Academic Publishers",
number = "1-4",

}

TY - JOUR

T1 - IgH translocations in multiple myeloma

AU - Bergsagel, Peter Leif

AU - Chesi, Marta

AU - Nardinp, E.

AU - Lim, R. S.

AU - Shonukan, O.

AU - Kuehl, W. M.

PY - 1998

Y1 - 1998

N2 - Based on our summary presentation of the information described above, we propose a working multistep model of the molecular pathogenesis of myeloma (Figure 2). The cell which gives rise to myeloma appears to have passed through the pathway that generates the long-lived plasma cell that has a phenotype similar to myeloma cells. Thus the oncogenic events in myeloma either occur after or do not interfere with the normal maturation process that generates lone-lived plasma cell. Like a long-lived plasma cell, a myeloma cell has undergone three developmentally regulated changes in the DNA structure of the IgH and IgL loci, including productive V(D)J recombination of its IgH and IgL genes, somatic hypermutation of the IgH and IgL V regions, and productive IgH switch recombination to another IgH isotype. It is attractive to speculate that errors in one or more of these processes have caused genetic changes that contribute to the malignant process. A chromosome translocation to the IgH locus, most frequently into a switch region, is a nearly universal event in myeloma cell lines, and it appears to be equally frequent in primary tumor samples. We postulate that these translocations occur at the time of isotype switch recombination, on the non-productive allele. Since MGUS and myeloma share the same legitimate switch recombination on the productive allele, they may also share the same illegitimate switch recombination on the non-productive allele. The result of these translocations is to dysregulate the expression of an oncogene by juxtaposing it to the strong regulatory sequences of the IgH locus, resulting in immortalization of the malignant clone. The presence of intraclonal heterogeneity in the Ig hypervariable regions in MGUS indicates that these cells are still subject to somatic hypermutation. Perhaps spillover of this process onto ras or a tumor suppressor gene on chromosome 13 results in the selection of a single clone for malignant expansion. Following immortalization, the malignant cell establishes a supportive environment in the bone marrow with a network of cytokines, adhesion molecules and other co-stimulatory interactions with the stromal cells. Further mutations lead to stromal cell independent growth, and escape from the bone marrow microenvironment.

AB - Based on our summary presentation of the information described above, we propose a working multistep model of the molecular pathogenesis of myeloma (Figure 2). The cell which gives rise to myeloma appears to have passed through the pathway that generates the long-lived plasma cell that has a phenotype similar to myeloma cells. Thus the oncogenic events in myeloma either occur after or do not interfere with the normal maturation process that generates lone-lived plasma cell. Like a long-lived plasma cell, a myeloma cell has undergone three developmentally regulated changes in the DNA structure of the IgH and IgL loci, including productive V(D)J recombination of its IgH and IgL genes, somatic hypermutation of the IgH and IgL V regions, and productive IgH switch recombination to another IgH isotype. It is attractive to speculate that errors in one or more of these processes have caused genetic changes that contribute to the malignant process. A chromosome translocation to the IgH locus, most frequently into a switch region, is a nearly universal event in myeloma cell lines, and it appears to be equally frequent in primary tumor samples. We postulate that these translocations occur at the time of isotype switch recombination, on the non-productive allele. Since MGUS and myeloma share the same legitimate switch recombination on the productive allele, they may also share the same illegitimate switch recombination on the non-productive allele. The result of these translocations is to dysregulate the expression of an oncogene by juxtaposing it to the strong regulatory sequences of the IgH locus, resulting in immortalization of the malignant clone. The presence of intraclonal heterogeneity in the Ig hypervariable regions in MGUS indicates that these cells are still subject to somatic hypermutation. Perhaps spillover of this process onto ras or a tumor suppressor gene on chromosome 13 results in the selection of a single clone for malignant expansion. Following immortalization, the malignant cell establishes a supportive environment in the bone marrow with a network of cytokines, adhesion molecules and other co-stimulatory interactions with the stromal cells. Further mutations lead to stromal cell independent growth, and escape from the bone marrow microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=0032437771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032437771&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 47

EP - 52

JO - Cancer Research, Therapy and Control

JF - Cancer Research, Therapy and Control

SN - 1064-0525

IS - 1-4

ER -